MRFR Year End Sale
Bronchial Leiomyoma Market Research Report – Global Forecast till 2030

Bronchial Leiomyoma Market Research Report: By Site (Bronchi, Trachea), Diagnosis (Imaging, Blood Sampling, Biopsy), Treatment (Surgery, Bronchoscopy), End User (Hospitals & Clinics, Academic Institutes, Research Organization) - Global Forecast till 2030

ID: MRFR/Pharma/3418-HCR | | Region: Global | 90 Pages         

Bronchial Leiomyoma Market Scenario:


The bronchial leiomyoma market is expected to reach USD 11,481.38 Million by 2030 at 8.90% CAGR during the forecast period 2022-2030.
A bronchial leiomyoma is a rare form of lung tumor, which affects the lower respiratory tract tissues including bronchi, trachea, and other lung tissues. Bronchial leiomyoma constitutes approximately 33%-45% of respiratory system leiomyoma. Mostly, bronchial leiomyoma arises from the smooth muscle tissue lining of the bronchi and grow as solitary tumors being attached to the sides of the bronchi.  With the increasing prevalence of the lung cancer, the cases of the bronchial leiomyoma are estimated to increase, which is likely to drive the market growth during the forecast period 2017-2023.  In 2017, according to the American Cancer Society, about 222,500 new cases of lung cancer are reported leading to 155,870 deaths. Moreover, increasing per capita healthcare expenditure, developing healthcare sector are expected to boost the market growth during the forecasted period. In 2015, according to the Centres for Disease Control and Prevention, in the U.S. the total healthcare expenditure accounted for 17.8% of the total gross domestic product (GDP), which accounted for USD 3.2 trillion. Moreover, the per capita healthcare expenditure of the U.S. was about USD 9,990 within the same year. However, the complexity of diagnosis and treatment along with the lack of awareness of the disease may restrain the Bronchial Leiomyoma market growth during the forecast period. 


Intended Audience



  • Pharmaceutical companies

  • Biotechnological institutes

  • Government and Private Laboratories

  • Research and Development (R&D) Companies

  • Medical Research Laboratories

  • Market Research and Consulting Service Providers


Figure 1:- Bronchial leiomyoma market share, by region Bronchial Leiomyoma Market


Sources: WHO, annual reports, press release, white paper, and company presentation 


Segmentation


The bronchial leiomyoma market is segmented on the basis of the site, diagnosis, treatment, and end users.


On the basis of the site, the market is segmented into bronchi, trachea, and others.


On the basis of the diagnosis, the market is segmented into imaging, blood sampling, biopsy, and others. The imaging segment is sub-segmented into X-rays, CT scan, PET scan, and others. The blood sampling segment is sub-segmented into liver function test, thyroid profiling, renal function test, and others. 


On the basis of the treatment, the market is segmented into surgery, bronchoscopy, and others.


On the basis of the end users, the market is segmented into hospitals & clinics, academic institutes, research organization, and others. 


Regional Analysis


The Americas dominate the bronchial leiomyoma market owing to a well-developed healthcare sector. Additionally, increasing number of patients, increasing healthcare expenditure have boosted the growth of the Americas market. Moreover, the presence of the global players like Eli Lilly and Company., Pfizer Inc., and GlaxoSmithKline Plc. and developed economies like the U.S. and Canada within the region fuel the market growth.


Europe is the second largest bronchial leiomyoma market, which is followed by Asia Pacific. Availability of funds for research, huge patient population, and government support for research & development drive the European market.


Asia Pacific is the fastest growing region for the market due to the presence of a huge patient population and continuously developing economies like India and China. Moreover, the untapped market of the region has huge opportunities for the Bronchial Leiomyoma Market growth.


On the other hand, the Middle East & Africa owns the least share of the bronchial leiomyoma market due to the presence of poor economy, especially, in the African region, which has low per capita income. Moreover, stringent government policies may restrain the growth of the market in the African region. Majority of the market of this region is held by the Middle East due to a well-developed healthcare sector and huge healthcare expenditure. 


Research Methodology Global bronchial leiomyoma market


Sources: WHO, annual reports, press release, white paper, and company presentation 


 


Key players in the bronchial leiomyoma market: Hoffmann-La Roche Ltd (Europe), AstraZeneca (Europe), Eli Lilly and Company. (U.S.), Sanofi (Europe), Pfizer Inc. (U.S.), GlaxoSmithKline Plc. (U.S.), ArQule. (U.S.), Boehringer Ingelheim GmbH (Europe), and others.



Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

bronchial leiomyoma market is projected to grow at approximately 8.90% CAGR during the assessment period (2022-2030).

Increasing per capita healthcare expenditure and developing healthcare sector are major tailwinds pushing the growth of the global bronchial leiomyoma market.

Complexity of diagnosis & treatment and the lack of awareness regarding the disease are major growth impeders for the global bronchial leiomyoma market.

North America holds the largest share in the global bronchial leiomyoma market, followed by Europe and the Asia Pacific, respectively.

Hoffmann-La Roche Ltd (Europe), Eli Lilly and Company. (U.S.), AstraZeneca (Europe), Sanofi (Europe), Pfizer Inc. (U.S.), ArQule. (U.S.), GlaxoSmithKline Plc. (U.S.), and Boehringer Ingelheim GmbH (Europe), are some of the top players operating in the global bronchial leiomyoma market.